Clinical Development of Gamitrinib, a Novel Mitochondrial-Targeted Small Molecule Hsp90 Inhibitor
Abstract
Considerable progress has been made during the past budget cycle on all of the specific tasks set forth in the SOW for the present proposal. The overarching goal of Specific Aim 1 (months 0-12 of award) has been accomplished, with the identification of a novel metabolomics protein signature of Gamitrinib anticancer activity, in vivo (i), the characterization of protein biomarkers of Gamitrinib function in genetic models of prostate cancer (ii), and the further biochemical characterization of the target of Gamitrinib, TRAP-,1 in tumor bioenergetics and metabolic reprogramming (iii). Altogether, the work supported by the present award led to the publication of two articles directly relevant to the scopes of the present SOW (Chae et al Nat Comm. 4:2139; Lisanti et al Cell Rep 617:7), the submission for publication of a third original article (Ghosh et al submitted), and the presentation of some of the SOW research findings at a national conference (Keystone Conference on Mitochondrial Dynamics and Physiology, Santa Fe, NM -18/2/2014 23/2/2014).
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 2014
- Accession Number
- ADA610693
Entities
People
- Dario C Altieri
Organizations
- Wistar Institute